Abiopharma

🔍 WHITMAN MARGARET C (Director)

Company: CoreWeave, Inc. (CRWV)

Report Date: 2026-03-14

Detailed Transactions and Holdings:

• Acquired 1,200 shares of Class A Common Stock (Direct)
  Date: 2026-03-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,080.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 120 shares of Class A Common Stock (Direct)
  Date: 2026-03-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,200.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,200 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 9,560.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F3
• Sold 120 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-14 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock upon settlement.
• F2: The award vests ratably as to approximately 1/12 of the total award on the fourteenth calendar day of June, September, December, and March, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on June 14, 2025.
• F3: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
• F4: The award vested ratably as to approximately 1/4 of the total award on the fourteenth calendar day of June, September, December, and March, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vested on June 14, 2025.